Advanced Brain Monitoring, Inc. (ABM) announces the issuance of new patents covering the assessment of treatment efficacy resulting from supine sleep restriction by the United States Patent and Trademark Office (U.S. Patent No. 10,638,973) and by the Australian Commissioner of Patents (AU Patent No. 2018200573).
The claims broadly limit other positional therapy feedback devices from assessing nightly utilization, time in the supine and non-supine position, number of nightly supine attempts, and user responsiveness to feedback. The claims apply to either vibrotactile or auditory feedback delivered at the chest, neck, or forehead.
“We are proud the technological innovation of the Night ShiftTM Sleep Positioner was acknowledged with its fourth U.S. and fourth international patent,” stated Daniel J. Levendowski, a co-inventor and President of ABM. “These patents add to the Night Shift’s intellectual property portfolio which also restricted others from delaying feedback to allow the user time to fall asleep [e.g., 15-minutes] or adapting feedback intensity to the needs of the user.”
For more information, contact: Daniel J. Levendowski
Source: Advanced Brain Monitoring
Be the first to comment